Yahoo
    Stockholm - Delayed Quote SEK

    Hansa Biopharma AB (publ) (HNSA.ST)

    39.34 0.00 (0.00%)
    At close: October 30 at 12:59:39 PM GMT+1
    Loading Chart for HNSA.ST
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

    Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
    PR Newswire 8d ago
    Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week

    Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week
    PR Newswire 8d ago
    Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering

    Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
    PR Newswire 30d ago
    Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

    Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
    PR Newswire 3mo ago
    Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA

    Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
    PR Newswire 3mo ago
    SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma

    SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma
    GlobeNewswire 3mo ago
    Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

    Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
    PR Newswire 5mo ago
    Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

    Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
    PR Newswire 5mo ago
    SERB signs agreement to acquire Idefirix rights for $133.6m

    SERB signs agreement to acquire Idefirix rights for $133.6m
    Pharmaceutical Technology 5mo ago
    SERB signs agreement to acquire Idefirix rights for $133.6m

    SERB signs agreement to acquire Idefirix rights for $133.6m
    Hospital Management 5mo ago
    Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

    Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
    PR Newswire 5mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: